drugset / Trial / NCT06561152
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Non-randomizedSequentialOpen-labelTreatment
Summary
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
Timeline
- Start
- 2025-02-10
- Primary completion
- 2027-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Tagraxofusp | Protein / enzyme biologic | 12 ug/kg | Intravenous |